An embryo-screening service is drawing sharp criticism from scientists, ethicists and faith leaders, who say the technology turns parents into shoppers and children into products. Here’s what you need to know about the genetic optimization controversy:

The Nucleus Genomics platform

Manhattan startup markets genetic optimization tool:

The company’s marketing approach

Nucleus promotes reproductive freedom argument:

The founder’s defense

25-year-old CEO frames technology as evolution:

Heritage Foundation criticism

Policy analyst warns about selection criteria:

Catholic bioethics concerns

Religious leader condemns embryo quality assessment:

Social media backlash

Platform faces “dystopian” criticism online:

Scientific reliability concerns

Polygenic scores face clinical acceptance challenges:

The “new standard” concern

Ethics expert fears affluent adoption pressure:

Research investment criticism

Heritage analyst warns about misdirected scientific focus:

Industry expansion expectations

Nucleus reportedly first of several similar companies:

The broader philosophical debate

Critics question insufficient ethical consideration:

Read more:

• Genetic “optimization” sparks outcry as critics say embryo ranking treats children like products

This article is written with the assistance of generative artificial intelligence based solely on Washington Times original reporting and wire services. For more information, please read our AI policy or contact Ann Wog, Managing Editor for Digital, at awog@washingtontimes.com

The Washington Times AI Ethics Newsroom Committee can be reached at aispotlight@washingtontimes.com.